Company profile: Avidea Technologies
1.1 - Company Overview
Company description
- Provider of polymer-based drugs delivering nanoparticle vaccines for cancer treatment and infectious diseases, using uniform-size nanoparticles designed to target specific tissues and cell populations.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Avidea Technologies
Lycia Therapeutics
HQ: United States
Website
- Description: Provider of lysosome-targeting chimeras (LYTAC) technology for developing therapeutics that target and degrade extracellular and membrane-bound proteins for a range of diseases. Offers the LYTAC platform and a discovery pipeline of degraders for autoimmune and inflammatory conditions and cancer, and maintains a strategic collaboration with Lilly focused on immunology and pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lycia Therapeutics company profile →
DiaCarta
HQ: United States
Website
- Description: Provider of precision molecular diagnostics, including CE/IVD-marked KRAS detection, for cancer screening, monitoring, and therapy guidance. Offerings include RadTox for real-time cfDNA treatment response; ColoScape for colorectal screening and FIT-positive triage via plasma cfDNA changes; QClamp for sensitive ctDNA mutation detection; OptiSeq Colorectal Cancer NGS Panel for actionable mutations; Oncuria urine biomarkers; and custom mini-MRD panels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DiaCarta company profile →
Biomea Fusion
HQ: United States
Website
- Description: Provider of precision oncology and metabolic disease therapeutics based on novel covalent small molecules, including BMF-219, an oral investigational menin inhibitor for genetically defined cancers (AML, ALL, DLBCL, MM, CLL) and type 2 diabetes by enabling beta-cell proliferation and function; BMF-500, an investigational oral FLT3 inhibitor for AML; and the FUSION System, a platform for designing covalent small molecule therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomea Fusion company profile →
eTheRNA Immunotherapies
HQ: Belgium
Website
- Description: Provider of mRNA and lipid nanoparticle solutions for nucleic acid drug delivery, offering LNP platforms and customized LNP development using proprietary ionizable lipid libraries, plus LNP formulations for systemic cancer vaccines, intra-tumoral immuno-oncology, intramuscular prophylactic vaccines, and autoimmune diseases designed to maximize mRNA expression, efficacy, tolerability, and immune tolerance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eTheRNA Immunotherapies company profile →
AdnaGen
HQ: Germany
Website
- Description: Provider of molecular genetic diagnostic testing systems for medical and clinical research laboratories, offering AdnaTest kits with reagents for immunomagnetic selection, mRNA isolation, and multiplex RT-PCR for tumor diagnostics, and focusing on genetic pre-disposition.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AdnaGen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Avidea Technologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Avidea Technologies
2.2 - Growth funds investing in similar companies to Avidea Technologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Avidea Technologies
4.2 - Public trading comparable groups for Avidea Technologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →